ArticleRheumatology advances in practice2026

Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.

Irene Monjo-Henry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.